Cochlear implantation: an opportunity for drug development
Related Experiment Video
Updated: Jun 15, 2026

Cochlear Implant Surgery and Electrically-evoked Auditory Brainstem Response Recordings in C57BL/6 Mice
Published on: January 9, 2019
Hinrich Staecker1, Claude Jolly, Carolyn Garnham
1Department of Otolaryngology Head and Neck Surgery, University of Kansas School of Medicine, Kansas City, KS 66160, USA.
Abstract:
For many years, the fields of inner ear pharmacology and hearing devices have progressed in parallel with limited interaction. Recently, there has been a considerable advancement in our understanding of the inner ear and its pathologies. Cochlear implantation is now being adapted for patients with considerable residual hearing but minimal benefit from hearing aids. A major consequence is the recognition that devices can be implanted into the partially deaf inner ear with minimal loss of hearing. This opens the door to the concept of local drug treatment of the inner ear using implantable devices. The evolution of cochlear implantation thus presents us with an opportunity to develop a range of local pharmacologic interventions to prevent hearing degeneration.
